The role of molecular genetic analysis in the diagnosis of primary ciliary dyskinesia by Kim, R.H. et al.
ORIGINAL RESEARCH
The Role of Molecular Genetic Analysis in the Diagnosis
of Primary Ciliary Dyskinesia
Raymond H. Kim1,2, David A. Hall3,4, Ernest Cutz5,6, Michael R. Knowles7, Kathleen A. Nelligan8, Keith Nykamp9,
Maimoona A. Zariwala10, and Sharon D. Dell2,8,11
1Division of Clinical and Metabolic Genetics; 5Division of Pathology; 8Child Health Evaluative Sciences, and 11Division of Respiratory
Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada; 2Department of Pediatrics; 4Department of Medicine,
and 6Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; 3Division of Respirology,
St. Michael’s Hospital, Toronto, Ontario, Canada; 7Department of Medicine, and 10Department of Pathology and Laboratory Medicine,
University of North Carolina School of Medicine, Chapel Hill, North Carolina and 9Prevention Genetics, Marshfield, Wisconsin
Abstract
Rationale: Primary ciliary dyskinesia (PCD) is an autosomal
recessive genetic disorder of motile cilia. The diagnosis of PCD has
previously relied on ciliary analysis with transmission electron
microscopy or video microscopy. However, patients with PCD may
have normal ultrastructural appearance, and ciliary analysis has
limited accessibility. Alternatively, PCD can be diagnosed by
demonstrating biallelic mutations in known PCD genes. Genetic
testing is emerging as a diagnostic tool to complement ciliary analysis
where interpretation and access may delay diagnosis.
Objectives: To determine the diagnostic yield of genetic testing
of patients with a confirmed or suspected diagnosis of PCD in
a multiethnic urban center.
Methods: Twenty-eight individuals with confirmed PCD on
transmission electron microscopy of ciliary ultrastructure and 24
individuals with a probable diagnosis of PCD based on a classical
PCD phenotype and low nasal nitric oxide had molecular analysis of
12 genes associated with PCD.
Results:Of49 subjectswhounderwent ciliary biopsy, 28 (57%)were
diagnosed with PCD through an ultrastructural defect. Of the 52
individuals who underwent molecular genetic analysis, 22 (42%)
individuals had two mutations in known PCD genes. Twenty-four
previously unreported mutations in known PCD genes were
observed. Combining both diagnostic modalities of biopsy and
molecular genetics, the diagnostic yield increased to 69% compared
with 57% based on biopsy alone.
Conclusions: The diagnosis of PCD is challenging and has
traditionally relied on ciliary biopsy, which is unreliable as the sole
criterion for a definitive diagnosis. Molecular genetic analysis can be
used as a complementary test to increase the diagnostic yield.
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Primary ciliary dyskinesia (PCD) is
a genetically heterogeneous autosomal
recessive disease of motile cilia with an
incidence of approximately 1/16,000 live
births. Clinical manifestations include
chronic bronchitis, neonatal respiratory
distress, bronchiectasis, sinusitis, otitis
media, situs inversus, andmale infertility (1).
The differential diagnosis of PCD includes
respiratory disease, such as cystic fibrosis,
asthma, and interstitial lung disease, and other
system diseases, such as gastroesophageal
reflux, immunodeficiency, and allergic rhinitis,
often delaying the diagnosis, especially in the
absence of situs inversus (2).
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The diagnosis of PCD combines clinical
characteristics, diagnostic investigations,
and pathology. However, due to its clinical
variability and limitations of current testing
modalities, the diagnosis of PCD is often
uncertain (3). The gold standard for PCD
diagnosis traditionally has been
transmission electron microscopy (TEM)
of ciliary biopsy showing a ciliary
ultrastructural defect (1). Analysis of ciliary
beat pattern using video microscopy has
also been shown to be helpful in the
diagnosis of PCD (1, 2). However, ciliary
biopsy poses the problems of being
uncomfortable, being available only in
a very limited number of tertiary care
hospitals, and having a significant false-
negative and false-positive rate (4).
A number of research tests, including
nasal nitric oxide and radioactive
mucociliary clearance studies, help to
phenotype patients who have nondiagnostic
ciliary pathology (1, 2). However, these
specialized diagnostic tests are not offered
in most institutions and are not reliable in
preschool children, limiting their usefulness
for early diagnosis. A major limitation for
the understanding of PCD is the lack of
a definitive diagnosis in many individuals
with a PCD phenotype. With the ongoing
discovery of genes associated with PCD,
molecular genetic analysis is emerging as an
accessible and standardized diagnostic test
where more than 50% of PCD patients
possess two disease-causing mutations
in trans (1). Furthermore, genetic testing
allows for carrier testing, prenatal testing,
and genetic counseling. However, the role
and cost-effectiveness of genetic testing in
the diagnosis of PCD has yet to be fully
evaluated (3).
Motile cilia are composed of nine
peripheral microtubule doublets
surrounding a central microtubular pair
(“912” arrangement) along with
microtubular-associated proteins, such as
inner dynein arms (IDA), outer dynein
arms (ODA), radial spokes, and nexin links
(1). There are currently 24 genes identified
in nonsyndromic PCD, and each is
associated with a specific ciliary
ultrastructural defect. ODA defects are
observed in the majority of patients with
PCD (5), and mutations in seven genes
(DNAH5, DNAI1, DNAI2, DNAL1,
TXNDC3, CCDC114, and ARMC4) have
been identified in such patients (6–13).
Mutations in LRRC50/DNAAF1, KTU/
DNAAF2, DNAAF3, CCDC103, HEATR2,
LRRC6, ZMYND10, and DYX1C1 cause
both ODA and IDA defects (14–22).
Central microtubular pair (CP)
abnormalities are seen with mutations in
RSPH4A, RSPH9, and RSPH1 (23, 24).
Radial spoke defects associated with
CCDC39 and CCDC40 have been further
characterized to involve IDA and nexin-
links (nexin regulatory complexes) (25–27).
However, normal cilia or very subtle ciliary
ultrastructural abnormalities are observed
in patients with mutations in four genes
associated with PCD: DNAH11, HYDIN,
CCDC 164, and CCDC65 (28–31).
Furthermore, not all ciliary specimens are
adequate for TEM, making the diagnosis
of PCD solely on the basis of TEM difficult
(4, 5).
At the start of our study, 12 genes
were known to be involved in PCD and
were being offered for clinical molecular
genetic analysis. Due to the challenges in
the diagnosis of PCD, we undertook
a study to compare the diagnostic yield of
molecular genetic analysis with that of




Inclusion criteria for this study were patients
who have either (1) definite PCD based on
clinical phenotype plus a recognized ciliary
ultrastructural defect, or (2) probable PCD
based on the clinical phenotype and a low
nasal nitric oxide (,100 nl/min) in patients
5 years and older who were able to perform
this test reliably using the standard
technique of exhalation against a resister
(32). The empirical cut point of 100 nl/min
was based on the largest previously
published case series of patients with PCD
and published normative values (33, 34).
For patients who were given a clinical
diagnosis of PCD with an inconclusive
biopsy under the age of 5 years, only those
who were able to reliably perform nasal
nitric oxide testing at a later age and
met our inclusion criteria were included
in our study sample to avoid diagnostic
misclassification that may result from
indiscriminate nasal nitric oxide levels in
children younger than age 5 years (35). The
patients were evaluated at the Hospital for
Sick Children (n = 42) and St Michael’s
Hospital in Toronto (n = 10). A
retrospective chart review was conducted,
and collected data elements included
personal and family medical history,
diagnostic investigations, nasal nitric
oxide, the results of the TEM analysis
of the biopsies of cilia, and clinical
genetic testing.
Mutation Profiling and Analysis
All patients enrolled in this study had
clinical genetic testing conducted on 12
genes, mutations that have been implicated
in PCD. DNAwas extracted from peripheral
blood and analyzed at Prevention Genetics,
Wisconsin in a Clinical Laboratory
Improvement Amendments–approved
laboratory. Bidirectional Sanger Sequencing
was conducted interrogating all coding
exons of each gene, plus 50 base pairs
of flanking noncoding DNA on either
side of each exon. Genes were tested in
a sequential fashion until one mutation was
identified. If a second pathogenic mutation
was not identified, the next gene in the
panel was sequenced. For individuals with
no mutation identified, all 12 genes were tested.
Genes were analyzed in the following order,
DNAH5 (RefSeq: NM_001369.2), DNAI1
(RefSeq: NM_012144.2), CCDC39 (RefSeq:
NM_181426.1), CCDC40 (RefSeq:
NM_017950.2), DNAI2 (RefSeq: NM_023036.4),
DNAH11 (RefSeq: NM_003777.3), RSPH9
(RefSeq: NM_152732.4), RSPH4A (RefSeq:
NM_001010892.2), KTU/DNAAF2
(RefSeq: NM_018139.2), LRRC50/DNAAF1
(RefSeq: NM_178452.4), TXNDC3 (RefSeq:
NM_016616.4), and DNAL1 (RefSeq:
NM_031427.3). Prioritization was based on
previous reports of mutation frequency for
each gene (1). For example, DNAH5 is
reported to be the most frequently mutated
gene (15–21%), followed by DNAI1 (2–9%),
CCDC39 (2–10%), and CCDC40 (1–8%)
(1). DNAI2 is reportedly mutated in
approximately 2 to 4% of patients with
PCD, and DNAH11 is found in
approximately 6%. However, DNAI2 is
a much smaller gene and less costly to
sequence than DNAH11; therefore, DNAI2
was tested before DNAH11, with the goal
of reducing overall sequencing costs. At
the time of design, very little mutation
frequency information was available for the
remaining genes. As a result, these were
ordered based on gene size, from smallest
to largest, again to help reduce the costs of
sequencing.
If a variant of unknown significance
(VUS) was encountered, the ordering
clinician would examine the VUS very
ORIGINAL RESEARCH
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carefully and assess its pathogenicity before
proceeding with the next gene for testing.
A variety of criteria were used to predict
the pathogenicity of the variant. A variant
would be considered disease causing if it was
found in conjunction with a mutation in
the same gene and predicted to be
deleterious through three protein prediction
programs: SIFT, PolyPhen-2, and
MutationTaster (36–38).
Results of genetic mutation testing were
categorized into homozygote (two identical
pathogenic mutations on a single PCD
gene), compound heterozygote (two
different pathogenic mutations on a single
PCD gene), heterozygote (one pathogenic
mutation on a PCD gene), or no mutations.
Having two pathogenic mutations in
a single PCD gene (either homozygote or
heterozygote) was considered diagnostic
for PCD.
This study was approved by the
Research Ethics Boards of the Hospital for
Sick Children and St Michael’s Hospital.
Results
Clinical Phenotype
A total of 52 patients from 45 families with
probable or definite PCD were enrolled in
the study. Twenty-six were male (50%) and
26 were female (50%), with an age range
of 12 months to 55 years. Thirty-eight
families had only one member affected, and
seven families had two individuals affected.
The predominant ethnicities were white
(50%) and Pakistani (29%), and parental
consanguinity was present in 15 (33%)
families. Situs solitus was present in 28
individuals (53%), whereas 21 (40%) had
situs inversus, and 3 had situs ambiguous.
The majority of patients experienced
neonatal respiratory distress (85%), otitis
media (75%), bronchiectasis (75%), and
sinusitis (94%).
Ultrastructural Analysis of Cilia
Forty-nine patients had a ciliary biopsy
at our center and were tested for
ultrastructural defects by TEM using
a qualitative and quantitative approach as
previously described (5). Twenty-eight
(57%) patients had clear ciliary defects, six
(12%) had inconclusive findings, six (12%)
samples had an inadequate number of
ciliated cells for TEM analysis, nine (18%)
samples had no apparent defect, and three
individuals refused to have biopsy. Of the
28 individuals with confirmed ciliary
defects, 13 had isolated ODA defects, 6 had
IDA1CP defects, and 9 had combined
ODA1IDA defects.
Mutation Profile
Patients with confirmed ciliary defects and
positive genetic results. Eighteen patients
(64%) from 15 families with confirmed
ciliary defects were found to have at least
one mutation (Table 1). In these patients,
DNAH5 was the most commonly mutated
gene, found in eight families (53%),
followed by CCDC40 and CCDC39 found in
two families (13%) each, and DNAI2 and
DNAAF2/KTU in one family (6%) each.
Consistent with previous reports, all
patients with DNAH5 or DNAAF2/KTU
mutations had isolated ODA defects or
combined ODA1IDA defects (19, 39, 40).
Individual 23 was found to have
a novel nonsense mutation, c.10508G.A
(p.Trp3503*) and a second mutation,
c.10616G.A (p.Arg3539His), which is
similar to a previously documented
mutation, p.Arg3539Cys in a family with
PCD, which is believed to be involved in
a critical microtubule binding site in
DNAH5 (41), and we conclude this
mutation to be disease causing. Individual
31 was found to have a novel nonsense
mutation, c.9095C.G (p.Ser3032*) and
a second missense mutation, c.11437C.T
(p.Arg3138Trp), which is listed in
dbSNP (rs140948494) with a minor
allele frequency less than 0.1%
(www.1000genomes.org). The Arg3138
amino acid is conserved among primate,
chicken, frog, and fruit fly DNAH5
orthologs, and the Arg to Trp change is
predicted to be deleterious (36–38). Given
this allele’s rarity and amino acid change,
we conclude it to be disease causing.
Interestingly, family 127 had initial
interpretation of the biopsy as apparently
normal in individual 3 and inconclusive in
individual 33. Given the molecular findings
of two mutations in DNAH5, this prompted
a review of both individuals (3, 33) and
showed a classic ciliary defect with
shortened stubby ODAs in both individuals.
Also consistent with the literature,
patients with mutations in CCDC39 and
CCDC40 had IDA1CP defects (patients 5,
7, 22, 27, 34), without any apparent ODA
defects (26, 27). In four patients, only
a single heterozygous pathogenic mutation
in the DNAH5 was detected. Individual 12
had a biopsy initially reported as
inconclusive; however, when reviewed with
the molecular findings, the patient was
found to have a decreased number of ODA.
In total, 17 novel mutations were found in
the 15 families analyzed, along with 4
previously described mutations (39, 42).
Patients with nondiagnostic ciliary
biopsies and positive genetic results. Nine
(38%) of the patients with nondiagnostic
biopsies had at least one expected
pathogenic mutation (Table 2). Three
patients, all with positive parental
consanguinity, were found to have
homozygous mutations, of whom patient
11 was found to have an undocumented
missense variant (p.Leu2488Pro) in
DNAH5. The Leu2488 amino acid is
conserved among primate, chicken, frog,
and fruit fly DNAH5 orthologs; the Leu to
Pro change is predicted to be deleterious,
and we conclude it to be disease causing
(36–38). In addition, this patient also had
an undocumented heterozygous missense
variant (Arg121Cys; see Table E1 in the
online supplement) in DNAAF1/LRRC50
that is predicted to be benign.
Five patients from four different
families were found to be compound
heterozygotes. Two families, (128, 129) had
affected individuals with a normal ciliary
biopsy and two mutations in DNAH11,
which is consistent with the literature (28).
Of these, family 129 had one premature
truncating mutation in DNAH11 and
a novel missense p.Ile4122Ser variant.
Ile4122 is a well-conserved amino acid; this
change is predicted to be deleterious, and
we conclude this mutation to be disease
causing (36–38). Similarly, individual 8 had
one premature chain termination codon in
DNAH5 and a novel missense p.Ser3770Gly
variant, which is also predicted to be
pathogenic, and we conclude it to be disease
causing (36–38). In total, seven novel
mutations were found in the eight families,
along with five previously reported
mutations (28, 39, 43).
Patients with negative or inconclusive
genetic results. Ten patients (40%) with
confirmed ciliary defects did not have any
detectable mutations in any of the genes
tested (Table 3). Several rare and previously
undocumented variants were identified in
these patients (Table E1).
In 15 patients with nondiagnostic
ciliary biopsies, no disease-causing genetic
mutations were found. Two patients (14, 37)
without a confirmatory biopsy had affected
ORIGINAL RESEARCH
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siblings (patients 26 and 35, respectively),
both with combined ODA1IDA defects.
Thus, the suspicion of PCD in these two
patients is very high, even without
confirmation by ciliary biopsy or molecular
testing. Of the remaining 13 patients, 5 had
normal biopsies, 5 were inconclusive, 2
were inadequate, and 1 refused biopsy.
Based on their constellation of clinical
findings and low nasal nitric oxide, these
individuals were considered to be probable
PCD, although not confirmed on TEM or
molecular testing.
Diagnostic Yield
The diagnostic yield of ciliary biopsy alone
was 57% (28 of 49) (Tables 4 and 5).
Although 27 of 52 (52%) individuals had at
least one allele harboring mutation in the
12 PCD genes tested, only 22 of 52 (42%)
had two pathogenic mutations to confirm
the genetic diagnosis of PCD. In total, 36
individuals were diagnosed with PCD.
Fourteen were diagnosed through biopsy
alone, 8 with positive molecular results, and
14 had both diagnostic biopsies and two
disease-causing mutations. Overall, in this
population, adding clinically available
molecular genetic testing increased the
diagnostic sensitivity to 69% (36 of 52)
compared with 57% based on biopsy alone.
Discussion
The diagnosis of PCD is challenging and
currently relies on clinical features and
ciliary analysis. This is, to our knowledge,
the first study to assess and compare the
diagnostic usefulness of molecular genetic
analysis in a clinical setting. Historically,
patients have been diagnosed with PCD
based on TEM of ciliary tissue. However, the
diagnostic yield of such studies is reported
between 20 and 39% (4, 5), and many
individuals refuse to have such an invasive
procedure. In our study, a slightly higher
diagnostic yield of 57% was observed,
which may be a reflection of a different
patient selection process for biopsy in our
respective centers. In addition, inconclusive
biopsies were observed in six individuals
(12% of biopsy samples), which is
consistent with the 11 to 22% reported
previously (4, 5). The individuals with
inconclusive and inadequate biopsies were
offered repeat biopsy; however, the majority
refused. Two individuals (21, 50) who did
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inconclusive biopsies on their repeat
samples. This is a reflection of the
limitations of the overall diagnostic
usefulness of biopsy outside of the setting of
a clinical trial.
The diagnosis of PCD based on ciliary
biopsy alone is further complicated as
individuals with PCD and DNAH11,
HYDIN, CCDC164, and CCDC65mutations
have normal-appearing ciliary
ultrastructure by TEM (28–31).
Furthermore, some ultrastructural defects,
such as IDA and radial spoke defects, were
found to be false positives, having normal
TEM and beat pattern analysis on repeat
biopsy (44).
Genetic testing overcomes technical
limitations of ciliary analysis and has been
believed to increase the diagnostic yield in
patients with suspected PCD; however,
despite its convenience and availability, it is
not used routinely in clinical practice (3). Of
the 52 patients who underwent genetic
testing using the PCD panel of 12 genes, 22
individuals were found to have two
mutations in known genes associated with
PCD. Eight of these individuals had
nondiagnostic biopsies (not done,
inadequate, inconclusive, or normal),
providing an additional diagnostic yield of
12% compared with biopsy alone. Together,
genetic testing in conjunction with ciliary
biopsy provides an overall diagnostic rate of
69% for patients suspected of having PCD.
Furthermore, a molecular genetic result
offers carrier testing, prenatal testing, and
genetic counseling, which are not possible
with a pathologic diagnosis.
Ultrastructural analysis of cilia is
challenging, and TEM is prone to false-
positive and -negative results (4, 5). Our
studies used standard operating protocols,
and independent reviewers examined
samples. Unfortunately, such procedures
are not routine in most nonacademic
settings, particularly in nonpediatric
hospitals, and depending on the electron
microscopist’s familiarity with PCD
abnormalities, including sample
preparation and analysis, results may be
variable. Here, we demonstrate that the
molecular findings in patients can result in
review of the cilia ultrastructure and can
contribute to the pathologic interpretation
of the ciliary ultrastructure.
In addition, we document 24 previously
unreported genetic variants in various genes
(Table E2), of which five were classified as
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protein structure and the presence of
another pathogenic mutation. A total of 42%
of our patients were found to have two
mutations in a PCD gene, which is similar to
that reported in the literature (1).
Despite providing additional diagnostic
information on patients with two clearly
pathogenic mutations, molecular testing
conducted here may also require careful
interpretation and potentially further
testing. For example, in those individuals
with only one mutation detected, it
is difficult to definitively conclude
pathogenicity. Considering all five were
chain termination mutations, it is likely
these are the genes responsible for PCD in
these patients. Furthermore, the biopsy
results are congruent with the molecular
results, which can help guide further
molecular testing options. Because all
coding exons and intron/exon boundaries
were sequenced, additional studies, such as
deletion/duplication testing and mRNA
sequencing, will be necessary to identify
a possible second pathogenic allele and to
confirm that these mutations are causing
PCD in these patients. In vitro ciliary beat
frequency analysis would also be helpful in
determining the pathogenicity of these
cases. Alternatively, in some cases, biallelic
mutations in another gene that is not tested
may be responsible for the PCD phenotype.
Furthermore, the genetics of PCD are
not fully elucidated, as highlighted in
individual 50, who had one previously
documented predicted pathogenic VUS
(Table E1), c.520G.A in DNAI1 (40), and
a common TXNDC3 intronic variant,
c.271–27 C.T, previously documented in
a family with PCD (6). A second mutation
was not found in these two genes or in
the rest of the 10 PCD genes offered on the
panel. We can speculate that this individual
had two mutations on different genes;
however, digenic inheritance has not
previously been reported in PCD, and it is
difficult to ascertain if that is the case for
this patient. Another possibility is that this
individual carries a large deletion as the
second mutated allele or biallelic mutations
in another locus involved in PCD.
As more than one-third of individuals
with well-characterized PCD do not have
a mutation in associated PCD loci,
molecular genetic analysis may not provide
a diagnosis in all cases. In 25 individuals in
our study, genetic testing was not helpful,
in that testing 12 known genes resulted in
finding no mutations. This is a significant
portion (48%) of the population tested.
These individuals may possess a mutation
not detectable using the current molecular
assay and may benefit from testing the
12 other PCD-associated genes or gene-
discovery experiments. Due to the lag of
newly discovered PCD genes being clinically
available, our study may be underpowered
in terms of gene coverage. We expect
with the ongoing discovery of new PCD loci
that the proportion of individuals with
unknown PCD loci will decrease, increasing
the diagnostic contribution of molecular
genetic analysis.
There are a variety of limitations of this
current study. For a recessively inherited
disease such as PCD, a clear genetic
diagnosis requires two pathogenic
mutations on opposite chromosomes.
However, because parents have not been
tested, we cannot rule out the possibility that
both mutations are in cis for compound
heterozygotes or that a large intergenic
deletion is present in homozygotes
(Table 5). Given the clinical history of the
patients in this study, and the fact that
nearly all heterozygous mutations are
predicted strong loss of function
(i.e., frameshift, nonsense, splicing), we
presume patients with both mutations on
the same chromosome will be a minority.
Likewise, we expect individuals with a large
deletion covering a pathogenic mutation
to be a minority, because all but two (13,
27) are reported to be from consanguineous
parents. Nevertheless, parental studies are
currently underway.
Here, we describe a multiethnic cohort
of 52 patients with a suspected diagnosis
of PCD based on clinical history and
diagnostic investigations who subsequently
underwent molecular genetic analysis.
Importantly, eight individuals, whose
Table 4. Categorization of patients with primary ciliary dyskinesia based on diagnostic modality
Diagnostic Ciliary Biopsy Noncontributory Ciliary Biopsy† Totals
Diagnostic molecular genetics* 14 8 22
Nondiagnostic molecular genetics 14 16 30
Total 28 24 52
Molecular genetic analysis was conducted on the following genes: DNAH5, DNAI1, CCDC39, CCDC40, DNAI2, DNAH11, RSPH9, RSPH4A, DNAAF1,
DNAAF2, TXNDC3, DNAL1.
*Includes biopsies that were normal, inconclusive, inadequate, or not done.
†Two pathogenic mutations in a single primary ciliary dyskinesia gene.
Table 5. Categorization of genetic mutation zygosity based on ciliary biopsy results in 52 patients with primary ciliary dyskinesia
Homozygote Compound Heterozygote Heterozygote No Mutations
Diagnostic ciliary biopsy 6 8 4 10
Noncontributory ciliary biopsy* 3 5 1 15
Total 9 13 5 25
Molecular genetic analysis was conducted on the following genes: DNAH5, DNAI1, CCDC39, CCDC40, DNAI2, DNAH11, RSPH9, RSPH4A, DNAAF1,
DNAAF2, TXNDC3, DNAL1.
*Includes biopsies that were normal, inconclusive, inadequate, or not done.
ORIGINAL RESEARCH
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diagnosis was not obtained through a biopsy
of cilia, were found to have two mutations
in associated PCD genes, increasing the
combined diagnostic yield with genetic
testing to 69%. Based on these results, we
suggest genetic testing be conducted on all
individuals with a suspected diagnosis of
PCD in conjunction with ciliary biopsy
to maximize the diagnostic accuracy.
As not all the genes associated with PCD
are known, molecular genetic analysis
should not be considered the sole diagnostic
modality. However, genetic testing can
be used as a convenient initial test for
individuals in whom the clinical suspicion
for PCD is very high and access to ciliary
biopsy is limited. In addition, positive
molecular findings have the added
advantage of giving the family useful
genetic information for future prenatal
diagnosis and carrier testing studies.
Importantly, the diagnostic yield of
molecular analysis for PCD is predicted to
increase greatly as new PCD genes are
discovered and added to clinical
sequencing panels. As the diagnostic yield
increases and the cost of DNA sequencing
continues to drop, molecular analysis for
highly heterogeneous genetic diseases
such as PCD is expected to become an
invaluable and indispensable tool for
clinicians. n
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10 Olbrich H, Häffner K, Kispert A, Völkel A, Volz A, Sasmaz G, Reinhardt
R, Hennig S, Lehrach H, Konietzko N, et al. Mutations in DNAH5
cause primary ciliary dyskinesia and randomization of left-right
asymmetry. Nat Genet 2002;30:143–144.
11 Onoufriadis A, Paff T, Antony D, Shoemark A, Micha D, Kuyt B,
Schmidts M, Petridi S, Dankert-Roelse JE, Haarman EG, et al.;
UK10K. Splice-site mutations in the axonemal outer dynein arm
docking complex gene CCDC114 cause primary ciliary dyskinesia.
Am J Hum Genet 2013;92:88–98.
12 Pennarun G, Escudier E, Chapelin C, Bridoux AM, Cacheux V, Roger
G, Clément A, Goossens M, Amselem S, Duriez B. Loss-of-function
mutations in a human gene related to Chlamydomonas reinhardtii
dynein IC78 result in primary ciliary dyskinesia. Am J Hum Genet
1999;65:1508–1519.
13 Hjeij R, Lindstrand A, Francis R, Zariwala MA, Liu X, Li Y, Damerla R,
Dougherty GW, Abouhamed M, Olbrich H, et al. ARMC4 mutations
cause primary ciliary dyskinesia with randomization of left/right body
asymmetry. Am J Hum Genet 2013;93:357–367.
14 Duquesnoy P, Escudier E, Vincensini L, Freshour J, Bridoux AM, Coste
A, Deschildre A, de Blic J, Legendre M, Montantin G, et al. Loss-of-
function mutations in the human ortholog of Chlamydomonas
reinhardtii ODA7 disrupt dynein arm assembly and cause primary
ciliary dyskinesia. Am J Hum Genet 2009;85:890–896.
15 Horani A, Druley TE, Zariwala MA, Patel AC, Levinson BT, Van
Arendonk LG, Thornton KC, Giacalone JC, Albee AJ, Wilson KS,
et al. Whole-exome capture and sequencing identifies HEATR2
mutation as a cause of primary ciliary dyskinesia. Am J Hum Genet
2012;91:685–693.
16 Kott E, Duquesnoy P, Copin B, Legendre M, Dastot-Le Moal F,
Montantin G, Jeanson L, Tamalet A, Papon JF, Siffroi JP, et al. Loss-
of-function mutations in LRRC6, a gene essential for proper
axonemal assembly of inner and outer dynein arms, cause primary
ciliary dyskinesia. Am J Hum Genet 2012;91:958–964.
17 Loges NT, Olbrich H, Becker-Heck A, Häffner K, Heer A, Reinhard C,
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